Concepedia

Massimo Guidoboni

MG

Statistics

Publications

60

Citations

14.6K

H-Index

32

Active since

1990

Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico(Current)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Centro di Riferimento Oncologico

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

European Institute of Oncology

Massimo Guidoboni is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1990–2024

60

Publications

60

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2019 · 3.6K citations · Full text

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · Zurich Open Repository and Archive (University of Zurich) · 2022 · 557 citations

Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas

Andrés J.M. Ferreri, Massimo Guidoboni, Maurilio Ponzoni et al. · JNCI Journal of the National Cancer Institute · 2004 · 552 citations · Full text

High Prevalence of Activated Intraepithelial Cytotoxic T Lymphocytes and Increased Neoplastic Cell Apoptosis in Colorectal Carcinomas with Microsatellite Instability

Riccardo Dolcetti, Alessandra Viel, Claudio Doglioni et al. · American Journal Of Pathology · 1999 · 474 citations · Full text

, , +9

Rows per page

1–5 of 60